Ask AI
ProCE Banner Activity

HER2 in Focus: Experts Address Questions on Biomarker Testing in GI and Lung Cancer

Clinical Thought

Read this commentary in which experts address questions posed by an audience of healthcare professionals about HER2 testing methods, scoring, and therapeutic implications for gastrointestinal or lung cancer.

Released: May 18, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This educational activity is intended for pathologists, oncologists, and other laboratory and healthcare professionals involved in the precision care of patients with HER2-altered solid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement pathological procedures to identify patients with solid tumors who may benefit from HER2-targeted therapy consistent with the latest guidelines and expert recommendations

  • Assess the clinical implications of accurate HER2 evaluation for patients with solid tumors based on the latest clinical trial evidence and FDA approvals

  • Apply evidence-based approaches to standardize HER2 scoring and reporting in clinical practice

  • Collaborate with the multidisciplinary team to optimize treatment strategies for patients with HER2-altered solid tumors

Disclosure

Primary Author

Jonathan E. Dowell, MD: consultant/advisor/speaker: Genentech, Nuvation, Pfizer.

Rondell P. Graham, MBBS: researcher: Astellas; advisor: BioNTech, Daiichi Sankyo.

Geoffrey Ku, MD: researcher: AstraZeneca, Bristol Myers Squibb, CARsgen, Daiichi Sankyo, I-Mab, Jazz, Merck, Oncolys, Pieris, Triumvira, Zymeworks; consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Gilead, I-Mab, Jazz, Merck, Oncolys, Pieris, Zymeworks; other financial or material support: Dava Oncology, I-Mab.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA, has no relevant financial relationships to disclose.